216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors
B. Markman, P.M. LoRusso, A. Patnaik, E. Heath, A.D. Laird, B. van Leeuwen, K.P. Papadopoulos, J. BaselgaVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72148-7
File:
PDF, 72 KB
english, 2008